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ABSTRACT
Background/Aims Prematurely born infants undergo 
costly, stressful eye examinations to uncover the small 
fraction with retinopathy of prematurity (ROP) that needs 
treatment to prevent blindness. The aim was to develop a 
prediction tool (DIGIROP- Screen) with 100% sensitivity and 
high specificity to safely reduce screening of those infants 
not needing treatment. DIGIROP- Screen was compared 
with four other ROP models based on longitudinal weights.
Methods Data, including infants born at 24–30 weeks 
of gestational age (GA), for DIGIROP- Screen development 
(DevGroup, N=6991) originate from the Swedish National 
Registry for ROP. Three international cohorts comprised 
the external validation groups (ValGroups, N=1241). 
Multivariable logistic regressions, over postnatal ages 
(PNAs) 6–14 weeks, were validated. Predictors were birth 
characteristics, status and age at first diagnosed ROP and 
essential interactions.
Results ROP treatment was required in 287 (4.1%)/6991 
infants in DevGroup and 49 (3.9%)/1241 in ValGroups. To 
allow 100% sensitivity in DevGroup, specificity at birth was 
53.1% and cumulatively 60.5% at PNA 8 weeks. Applying 
the same cut- offs in ValGroups, specificities were similar 
(46.3% and 53.5%). One infant with severe malformations 
in ValGroups was incorrectly classified as not needing 
screening. For all other infants, at PNA 6–14 weeks, 
sensitivity was 100%. In other published models, sensitivity 
ranged from 88.5% to 100% and specificity ranged from 
9.6% to 45.2%.
Conclusions DIGIROP- Screen, a clinical decision support 
tool using readily available birth and ROP screening data 
for infants born GA 24–30 weeks, in the European and 
North American populations tested can safely identify 
infants not needing ROP screening. DIGIROP- Screen had 
equal or higher sensitivity and specificity compared with 
other models. DIGIROP- Screen should be tested in any new 
cohort for validation and if not validated it can be modified 
using the same statistical approaches applied to a specific 
clinical setting.
INTRODUCTION
Retinopathy of prematurity (ROP) is a sight- 
threatening disease occurring mainly in extremely 
preterm infants.1 Screening for severe ROP, for 
which treatment can prevent blindness, comprises 
repeated eye examinations following national 
screening guidelines, mostly using birth parameters, 
gestational age (GA) and birth weight.2 These exam-
inations are stressful, costly and very inefficient.3–6 
In Sweden and in the USA, only ~6% of screened 
infants need treatment for ROP.7 8 The number 
of ROP examinations and need for treatment 
are increasing over time with improved neonatal 
healthcare that increases the number of infants 
surviving extreme prematurity.9 10 A prediction 
model including known risk factors at birth and 
postnatal parameters using statistical approaches 
enabling risks to vary over time could identify the 
time to safely end ROP screening as well as iden-
tify low- risk infants requiring fewer or no ROP 
examinations. Such a clinical decision support tool 
would be valuable both for infants, and health 
economics. Reducing the number of examinations 
would not only reduce the stress and pain, but also 
for example, avoid the transport of infants to the 
screening unit, change of daily routines and poten-
tial exposure to infections during transport and 
at the hospital. Even if stress is minimised during 
ROP screening, the examinations may still affect 
the infants systemically with such as increased 
tachycardia and apnoeic episodes. From a health 
economics perspective, such models would help 
optimise the use of healthcare personnel to focus 
on the babies who need careful monitoring.
Many models predicting ROP requiring treat-
ment have been published during the past two 
decades, such as weight, insulin- like growth factor 
1, neonatal, ROP (WINROP), Colorado- ROP (CO- 
ROP), Children’s Hospital of Philadelphia- ROP 
(CHOP- ROP), postnatal growth and retinopathy 
of prematurity (G-ROP) and Omaha- ROP (OMA- 
ROP).11–20 A systematic review of 23 studies, 
performed by the American Academy of Ophthal-
mology (AAO) in 2016, developing or validating 
prediction models for different ROP outcomes 
found no model development study, and only one 
model validation study judged as good quality.21 22 
The AAO concluded that prediction model devel-
opment at the time was still in its early phase and 
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needed rigorous implementation of guidelines for generating 
prognoses, including larger sample sizes and assessment of 
generalisability.
Our research group has previously published the prediction 
model (WINROP) which was based on birth parameters with 
the addition of first longitudinal serum insulin- like growth 
factor 1 (IGF-1) levels (that were difficult to obtain), then based 
on postnatal growth reflecting postnatal IGF-1.11 12 22 23 This 
model, used to identify low- risk and high- risk infants, did not 
always achieve 100% sensitivity and had variable specificity. 
Recently, we published a prediction model for ROP requiring 
treatment, DIGIROP- Birth, for infants born at GA 24–30 weeks, 
estimating individual risks at an early stage based on birth char-
acteristics alone (GA, birth weight and sex), as weight measure-
ments at specific postnatal periods are not always available to 
the screening ophthalmologist and/or neonatologist. We applied 
statistical methods enabling description of the actual develop-
ment of risk for severe ROP postnatally for each individual 
infant.24
In the current study, we extended DIGIROP- Birth into 
DIGIROP- Screen to also include ROP progression data. Based 
on the estimated predictions we created a clinical decision 
support tool to reduce the burden of ROP screening sessions. 
As well as identifying infants who do not develop severe ROP 
in our cohort, we also sought to identify the time point when 
the longitudinal screening process could safely end in infants 
who had some risk of developing severe ROP during their post-
natal course. To our knowledge this has not been studied previ-
ously. Internal and external validations, and comparisons (with 
respect to sensitivity and specificity of predicting severe ROP) to 
four other published models (WINROP, CO- ROP, CHOP- ROP, 
OMA- ROP), were performed.12 16–18 The aim was to develop 
and validate models with 100% sensitivity to capture all infants 
requiring treatment and the highest specificity to reduce exam-
inations in infants not developing severe ROP in our cohort and 
the validation cohorts using parameters that were easily avail-
able to ophthalmologists. The algorithm must be validated in 
any new cohort before being adopted to show that the same 
100% sensitivity and high specificity apply. If 100% sensitivity 
and high specificity are not validated, using the same statistical 
approaches used in DIGIROP- Screen development the predic-
tion model can be modified for any new clinical setting.
MATERIALS AND METHODS
This study has followed the guidelines for Transparent Reporting 
of a multivariable prediction model for Individual Prognosis or 
Diagnosis.25
Study population
The data, including infants' birth characteristics and the timing 
of progression of ROP through stages and treatment, originate 
from the Swedish National Registry for ROP (SWEDROP) that 
is part of the Swedish Neonatal Register, and was initiated in 
2007.7 26 The registry has high coverage, ~97%, and collects 
data about the number of eye exams, dates for first and last eye 
exam, presence of ROP at the first eye screening, ROP stage, 
zone, plus disease, treatment, type of ROP, maximum stage and 
most central zone for ROP left and right eye and the date for 
first observation of respective ROP stage. The incomplete and 
missing data were validated against medical records. A study 
flowchart describing model development group and validation 
groups is presented in figure 1.
Model development group (DevGroup)
Of 7031 infants born at GA 24–30 weeks, between 1 January 
2007 and 24 October 2017, 6991 (99.4%) were eligible for 
inclusion in the model development group. Twenty- four (0.3%) 
infants were excluded due to missing birth characteristics data 
and 13 (0.2%) due to missing or inconsistent follow- up data. 
Additionally, three infants were identified as outliers during 
model development. They were treated despite not fulfilling 
treatment criteria for type 1 ROP (ROP stage 3 zone III, at the 
most one clock hour).
Validation groups (ValGroups)
Infants born at GA 24–30 weeks between 1 November 2017 
and 7 August 2018 (n=318) and registered in SWEDROP were 
considered for inclusion in the Swedish temporal validation 
Figure 1 Study flowchart. BIDMC, Beth Israel Deaconess Medical Center; GA, gestational age; ROP, retinopathy of prematurity; SWEDROP, Swedish 
national Registry for ROP.
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group. Four (1.3%) infants were excluded for missing data, 
leaving 314 (98.7%) eligible infants for validation.
Retrospectively collected data from 2011 to 2017 from a 
German site in Freiburg included 322 (96.7%) out of 333 infants 
born at GA 24–30 weeks and served as the German validation 
group.27 Eleven (3.3%) infants were excluded due to either 
missing birth weight or GA (n=4), or unavailable ROP progres-
sion data (n=7).
The US- BIDMC validation group included 258 (99.6%) out of 
259 infants born at GA 24–30 weeks between 2006 and 2009 
from the US site Beth Israel Deaconess Medical Center (BIDMC), 
Boston, Massachusetts.22 One infant was excluded due to 
unavailable ROP progression data. For this cohort, information 
about race and ethnicity was available in 240 (93.0%)/258 and 
used to test the model’s predictive ability for a white (n=177) 
and a non- white (n=63) population.
The US- Utah validation group included 347 (100%)/347 
infants born at GA 24–30 weeks between 2014 and 2019 from 
the US site John A. Moran Eye Center, Salt Lake City, Utah.
The two US cohort files contained infants' weekly weights 
and were used to compare four other ROP models (WINROP, 
CO- ROP, CHOP- ROP, OMA- ROP) using postnatal weight gain 
as input.12 16–18
In total, 1241 infants were included in the validation groups 
(ValGroups).
Study procedures
Fetal ultrasound was used to estimate GA in all cohorts. The 
postnatal age (PNA), postmenstrual age and GA are defined 
according to the American Academy of Pediatrics policy.28 Birth 
weight standard deviation scores (BWSDS) were calculated 
based on birth weight, GA and sex using a Swedish reference for 
800 000 healthy singletons (of ~1 million born) born at GA ≥24 
weeks during 1990–1999.29
Study outcome and predictors
The study outcome is ROP treated following early treatment 
for ROP criteria or if judged required by the examining/treating 
ophthalmologist.30 ROP stages were defined by the International 
Classification of ROP.31 The infant’s status (yes/no), age at the 
first sign of ROP and weeks since the first sign of ROP were 
potential predictors tested for inclusion in the DIGIROP- Screen 
model, besides the log- odds for the DIGIROP- Birth probabil-
ities  (log(probability/(1−probability))),  GA,  sex,  BWSDS  and 
important interactions. The final models included log- odds for 
the DIGIROP- Birth probabilities, infant’s status and age at the 
first sign of ROP and interaction between them. Data were anal-
ysed on patient- level, including first occurrence of any ROP as 
predictor and first ROP treatment as outcome.
Statistical analysis
Continuous variables were presented by mean, SD, median 
and range and categorical variables by number and percentage. 
The difference between DevGroup and ValGroups was tested 
using Fisher’s exact test for dichotomous variables, Mantel- 
Haenszel χ2 trend test for ordered categorical variables and 
Mann- Whitney U test for continuous variables. The estimated 
risk predictions from DIGIROP- Birth were applied at birth. 
Multivariable logistic regression was used for PNAs 6–14 weeks. 
PNA week 6 is the earliest week when infants are starting their 
screening per guidelines. By PNA week 14 it was expected that 
majority of ROP treatments have occurred. GA- specific cut- 
offs based on estimated probabilities for 100% sensitivity were 
retrieved from the models performed on DevGroup and used for 
implementation of the clinical decision support tool. Specificities 
and cumulative specificities that is a fraction of infants below 
the cut- off at the current time or earlier among the non- treated 
infants were obtained with 95% CI. Internal validation, exam-
ining the model’s reproducibility in its cohort, was performed by 
10- fold cross- validation. The Hosmer- Lemeshow test examined
goodness- of- fit and calibration of observed versus the estimated
number of events. External validation, analysing the model’s
generalisability/transportability in the cohorts from other
healthcare settings, populations and periods were assessed on
ValGroups by describing sensitivity, specificity and cumulative
specificity with 95% CI based on cut- offs for 100% sensitivity
obtained from DevGroup. In order to achieve the recom-
mended lower 95% limit for 100% sensitivity of 99%,~300
events (ROP treatment) were needed, that was fulfilled by the
DevGroup sample. Sensitivity and cumulative specificity/spec-
ificity with 95% CI were presented for DIGIROP- Screen and
the four ROP comparison models based on the two US external
validation cohorts combined. Detailed descriptions of the statis-
tical methods are available in online supplemental eappendix 1.
Graphical workflow of DIGIROP- Screen and four comparison
models are presented in online supplemental efigure 1.
All tests were two- tailed and p<0.05 was considered signif-
icant. Analyses were performed using SAS software V.9.4 (SAS 
Institute Inc, Cary, North Carolina, USA).
RESULTS
Study population
Birth characteristics and ROP progression for the DevGroup 
(N=6991) and the four cohorts included in the ValGroups 
(N=1241) are presented in table 1. In the DevGroup, 3158 
(45.2%) were girls. Mean GA was 28.3 (SD 1.9) weeks, mean 
birth weight 1146 (SD 339, range 307–3245) grams and mean 
BWSDS −1.03 (SD 1.37). In DevGroup and ValGroups, respec-
tively, 2026 (29.0%) and 502 (40.5%) were diagnosed with any 
ROP, and 287 (4.1%) and 49 (3.9%) were treated for ROP.
ValGroups included more girls, had lower average birth 
weight, differed with respect to the birth year and more infants 
experienced any ROP compared with DevGroup. Online supple-
mental etable 1 describes infant characteristics for the validation 
cohorts and online supplemental etable 2 for treated and not 
treated infants.
DIGIROP-Screen in model development group (DevGroup)
The multivariable logistic models for DIGIROP- Screen at birth 
and over PNAs 6–14 weeks are presented in online supple-
mental etable 3 and cut- offs based on estimated probabilities in 
online supplemental etable 4. Estimated probabilities for ROP 
treatment stratified by GA at birth (24–30 weeks) for different 
PNA are presented in online supplemental efigure 2 A–J. The 
area under the receiver operating characteristic curve (AUC) 
ranged between 0.91 and 0.93 (online supplemental etable 5, 
efigure 3). For selected cut- offs for 100% (95% CI: 98.7% to 
100%) sensitivity in DevGroup, specificity at birth was 53.1% 
(95% CI: 51.9% to 54.3%), cumulatively at 8 weeks 60.5% 
(95% CI: 59.3% to 61.7%) and cumulatively at 12 weeks PNA 
75.5% (95% CI: 74.5% to 76.5%) (table 2, online supplemental 
etable 6, efigure 4). The prediction models' contribution at 6, 7 
and 14 weeks PNA to the increase of cumulative specificity was 
negligible. Among infants flagged as not needing ROP screening 
already at birth 3179 (89.2%) were diagnosed with no ROP, 202 
(5.7%) with ROP stage 1, 137 (3.8%) with untreated stage 2 and 
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44 (1.2%) with untreated stage 3 (online supplemental etable 7). 
No infants born at GA 24 and 25 weeks could be released from 
ROP screenings at birth (figure 2A). Percentages of infants iden-
tified as possible to be released from ROP screenings over PNA 
stratified by GA at birth are presented in figure 2B.
Stratified by GA <28 and ≥28 weeks, specificity at birth was 
11.9% and 76.8%, and cumulatively up to 12 weeks 40.6% and 
95.5%, respectively (online supplemental etable 6). The corre-
sponding specificities for GA <30 weeks were 37.4% at birth 
and 67.1% cumulatively up to 12 weeks PNA.
Internal validation of DIGIROP-Screen in model development 
group (DevGroup)
Specificity, cumulative specificity and AUC with 95% CI 
obtained from the 10- fold cross- validation were obtained 
from logistic regression models developed on DevGroup 
(online supplemental etable 5 and 6). The AUC ranged 
between 0.90 and 0.94 (online supplemental etable 5). The 
specificity at birth was 48.0% (95% CI: 46.8% to 49.2%), 
and cumulatively up to PNA 8 weeks was 60.0% (95% CI: 
58.8% to 61.1%) for internal validation.
Hosmer- Lemeshow test was non- significant at all PNAs (online 
supplemental etable 3), indicating goodness- of- fit accepted as 
satisfactory, and showed a well- calibrated estimated versus the 
observed number of events.
External validation of DIGIROP-Screen in validation groups 
(ValGroups)
Individual risk predictions stratified by GA at birth (24–30 
weeks) over PNA are presented in online supplemental efigure 5.
Applying the same cut- offs on ValGroups, as those 
obtained for DevGroup (for 100% sensitivity), the specifici-
ties were 46.3% (95% CI: 43.4% to 49.2%) at birth, 53.5% 
(95% CI: 50.6% to 56.4%) cumulatively at 8 weeks and 
69.6% (95% CI 66.9% to 72.2%) cumulatively at 12 weeks 
PNA (table 2, online supplemental etable 6, efigure 6). In 
ValGroups, sensitivity was 100% (95% CI: 92.7% to 100%) 
for all models except for one infant at birth and PNAs 6 and 
7 weeks. By inclusion criteria for current ROP screening, 
this infant should have been followed and screened because 
of the medical indication. At birth (GA 30 weeks) the infant 
had VACTERL association (vertebral defects, anal atresia, 
cardiac defects, tracheo- esophageal fistula, renal abnormal-
ities, limb abnormalities) with severe intrauterine growth 
restriction.
Stratified by GA <28 and≥28 weeks, specificity at birth was 
11.3% and 69.7%, and cumulatively up to 12 weeks 35.4% and 
92.6%, respectively.
Figure 2C and online supplemental efigure 7 illustrate the 
number of infants who could potentially be released from 
ROP screening cumulatively over PNAs according to last 
examination reported in SWEDROP, according to DIGIROP- 
Screen in DevGroup and ValGroups.







Girls 3158 (45.2%) 607 (48.9%) 0.016





GA (full weeks) 0.0007
 24 427 (6.1%) 94 (7.6%)
 25 597 (8.5%) 114 (9.2%)
 26 781 (11.2%) 129 (10.4%)
 27 914 (13.1%) 187 (15.1%)
 28 1141 (16.3%) 239 (19.3%)
 29 1419 (20.3%) 236 (19.0%)
 30 1712 (24.5%) 242 (19.5%)













 2006–2007 543 (7.8%) 139 (11.2%)
 2008–2009 1331 (19.0%) 119 (9.6%)
 2010–2011 1303 (18.6%) 9 (0.7%)
 2012–2013 1369 (19.6%) 103 (8.3%)
 2014–2015 1445 (20.7%) 249 (20.1%)
 2016–2017 1000 (14.3%) 331 (26.7%)
 2018–2019 0 (0.0%) 291 (23.4%)
Any ROP 2026 (29.0%) 502 (40.5%) <0.0001






ROP treatment 287 (4.1%) 49 (3.9%) 0.87




Model development group includes data from Swedish National Registry for ROP, born at GA 
24–30 weeks (2007–2017).
Validation groups consist of four external validation cohorts, one from Sweden (later time 
period than in the model development group), one from Germany and two from USA.
For categorical variables, n (%) is presented. For continuous variables, mean (SD)/median 
(min; max) is given.
*P values should be interpreted with caution due to the large cohorts. Conclusions should be 
made based on the clinically relevant differences.
GA, gestational age; PNA, postnatal age; ROP, retinopathy of prematurity; ROP, retinopathy 
of prematurity; SDS, standard deviation score.
Table 2 Specificity with 95% CI for 100% sensitivity at birth and 
over postnatal weeks for model development group (N=6991), and 
external validation groups (N=1241)








At birth 53.1 (51.9 to 54.3) 46.3 (43.4 to 49.2)
Cumulatively at PNA 6 weeks 53.3 (52.0 to 54.5) 46.4 (43.5 to 49.3)
Cumulatively at PNA 7 weeks 54.2 (53.0 to 55.4) 47.2 (44.4 to 50.1)
Cumulatively at PNA 8 weeks 60.5 (59.3 to 61.7) 53.5 (50.6 to 56.4)
Cumulatively at PNA 9 weeks 67.6 (66.5 to 68.7) 61.2 (58.3 to 63.9)
Cumulatively at PNA 10 weeks 72.1 (71.0 to 73.2) 65.9 (63.1 to 68.5)
Cumulatively at PNA 11 weeks 75.3 (74.3 to 76.4) 69.3 (66.6 to 71.9)
Cumulatively at PNA 12 weeks 75.5 (74.5 to 76.5) 69.6 (66.9 to 72.2)
Cumulatively at PNA 13 weeks 80.6 (79.6 to 81.5) 75.2 (72.6 to 77.6)
Cumulatively at PNA 14 weeks 80.6 (79.7 to 81.6) 75.2 (72.6 to 77.6)
Model development group includes data from SWEDROP, born at GA of 24–30 weeks 
(2007–2017).
Validation groups consist of four external validation cohorts, one from Sweden (later time 
period than in model development group), one from Germany and two from USA.
Cumulative specificity at a certain PNA is calculated as a union of specificities up to and 
including that certain PNA.
*Cut- offs selected in model development group for sensitivity 100%.
†For validation groups, cut- offs obtained from model development group are applied. 
Sensitivity 100% for all postnatal weeks except for one infant at birth, and PNA 6 and 7 
weeks (sensitivity 48/49 at those time points), with severe comorbidity profile.
GA, gestational age; PNA, postnatal age; ROP, retinopathy of prematurity; SWEDROP, 
Swedish National Registry for ROP.
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Information about race and ethnicity was available in the 
US- BIDMC validation group. Stratifying by infants reported 
as white (n=177, one required ROP treatment) and those 
reported as non- white (n=63, three required ROP treat-
ment) infants, specificity at birth was 54.5% and 38.3%, and 
cumulatively up to 12 weeks 65.9% and 56.7%, respectively 
(online supplemental etable 6).
The AUC for the models at birth and over different PNAs 
ranged between 0.88 and 0.92 (online supplemental etable 5).
Comparison of DIGIROP-Screen to other ROP prediction 
models
DIGIROP- Screen was compared with four other published 
models using US validation groups, as comparison cohorts 
table 3.
With 100% sensitivity cut- off, DIGIROP- Screen versus 
CHOP- ROP17 had better specificity (48.7% vs 27.5%) at 8 
weeks and better specificity at 12 weeks PNA (63.6% vs 27.9%). 
DIGIROP- Screen versus OMA- ROP18 had the same sensitivity 
Figure 2 Illustration of infants born 24–30 weeks of gestational age released from screening for ROP according to: (A) risk predictions from 
DIGIROP- Screen at birth by gestational age in model development group (DevGroup), (B) risk predictions from DIGIROP- Screen over postnatal ages by 
gestational age in DevGroup, (C) last examination date reported in SWEDROP, and risk predictions from DIGIROP- Screen in DevGroup and validation 
groups (ValGroups). In (C), n and % are presented for time points: birth, postnatal ages 6, 8, 10, 12 and 14 weeks. ROP, retinopathy of prematurity; 
SWEDROP, Swedish National Registry for ROP.
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(96.0% vs 96.0%), but better specificity (46.2% vs 38.1 %). 
DIGIROP- Screen versus WINROP12 had better sensitivity 
(96.2% vs 88.5%) and similar specificity (45.1% vs 45.2%). 
DIGIROP- Screen applied at birth versus CO- ROP16 had similar 
sensitivity (96.2% vs 96.2%) and better specificity (41.0% vs 
9.6%).
Clinical implications
The DIGIROP- Screen prediction tool comprising automatically 
calculated individual risk predictions for infants born at GA 
24–30 weeks is available at www. digirop. com.32 Additionally, 
evaluations of the risks based on defined cut- offs provide infor-
mation whether any/further ROP examinations are required or 
not for 100% sensitivity (in these cohorts). Example illustra-
tions following a specific infant over screening PNAs planned 
for availability in the application are presented in online supple-
mental efigure 8.
DISCUSSION
In this study, we developed an ROP clinical decision support tool, 
DIGIROP- Screen, for infants born at GA 24–30 weeks, suitable 
for longitudinal use with ROP screening. The tool is developed 
to identify the time point for safe release of an infant from the 
ROP screening. DIGIROP- Screen is based on the infants’ birth 
characteristics (GA, birth weight and sex) and ROP data that are 
easily obtained at almost all medical facilities while performing 
routine ROP screening. Other models use longitudinal weights 
at specific intervals which are less readily available to ophthal-
mologists and less retrievable on a national level for all screened 
infants. The prediction tool applied to several cohorts of infants 
screened for ROP by current criteria in advanced neonatal inten-
sive care unit (NICU) settings, identified early ~45% of infants 
as not needing any ROP screening using only neonatal charac-
teristics and identified an additional 25% for whom screening 
may be terminated earlier than with today’s screening practice, 
thus potentially substantially and safely reducing the number of 
screening examinations. The prediction tool is made available 
as an online application, www. digirop. com, to clinicians world-
wide. This tool must be validated and assessed in each specific 
clinical setting, before being implemented for routine use. 
Using the same statistical approaches used in DIGIROP- Screen 
development the prediction model can be modified for any new 
clinical setting.
Studying a low- incidence disease requiring 100% sensitivity, 
that is, correctly identified all high- risk infants requiring ROP 
treatment, implies the need for access to very large datasets. 
The lower 95% confidence limit for sensitivity would need to 
approach 99%, as previously discussed.21 33 Our study, which 
included ~7000 infants and 287 endpoints (ie, ROP treat-
ment), reaches this goal. Larger datasets imply larger individual 
variability and thus also increased risk for outlying data in the 
cohort. Having the diagnostic cut- offs in such large datasets 
based on the individually estimated risks (potentially including 
outliers) together with the requirement of 100% sensitivity, 
most often results in low specificity, that is, correctly identified 
all low- risk infants not needing treatment that might be released 
from the ROP screening. In the external validation, DIGIROP- 
Screen demonstrated specificity of 46% at birth (11% for GA 
<28 weeks, 70% for GA ≥28 weeks), and 70% for data used 
up to postnatal week 12 (35% for GA <28 weeks, 93% for GA 
≥28 weeks), compared with 11% with the updated CHOP- ROP 
model using longitudinal weekly weights and 33% for the 
G- ROP algorithm that screens all infants <28 weeks of GA at
birth.17 34 Smaller datasets, on the other hand, including 191
to 560 infants in model development have resulted in higher
specificities ranging from 62% to 85% for achieved 100% sensi-
tivity.12 18 20 Nonetheless, in our US validation cohorts of ~600
infants, DIGIROP- Screen appeared to be a more accurate predic-
tion model than the four comparison models, for both sensi-
tivity and specificity. Unfortunately, the weight measurements at
10, 19, 20, 29, 30 and 39 postnatal days were not available for
DIGIROP- Screen precluding a full comparison to the G- ROP
screening criteria.34
The high performance of DIGIROP- Screen even at birth, 
applying only DIGIROP- Birth risk estimations, is achieved due 
to the availability of a large model development dataset and 
the most prominent risk factors for ROP treatment, GA and 
birth weight. However, as well known, these are not the only 
important risk factors, which is why the obtained probabilities 
showed high variability between GA that resulted in the decision 
to apply GA- specific cut- offs as scores rather than probabilities 
in the prediction tool.
Table 3 Comparison of DIGIROP- Screen versus other existing ROP prediction models
Comparison model and time point
N/N
Specificity (95% CI) (%)
N/N
Sensitivity (95% CI) (%)
DIGIROP- Screen Comparison ROP model DIGIROP- Screen Comparison ROP model

























































DIGIROP- Screen (at birth) vs













CHOP- ROP, Children’s Hospital of Philadelphia- ROP; CO- ROP, Colorado- ROP; OMA- ROP, Omaha ROP; PMA, postmenstrual age; PNA, postnatal age; ROP, retinopathy of prematurity; w, weeks; 
WINROP, weight, insulin- like growth factor 1, neonatal, ROP.
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The infant with congenital VACTERL association was incor-
rectly flagged as not needing ROP screening. In current clin-
ical practice, any very preterm baby with severe congenital 
malformations would have had continuous clinical and medical 
surveillance for ROP. The medical evaluation is of paramount 
importance, no matter how high predictive ability is achieved 
of any model. Likewise, babies born before 24 weeks of GA 
are all at a very high risk for developing ROP (89%) and all 
should be followed closely.24 Optimisation of screening through 
general prediction models for these babies is inapplicable and 
inappropriate.
Our study’s strength is the large national cohort, the valida-
tion datasets originating from two continents and the selected 
statistical methods. Development, validation and evaluation 
of the prediction tool followed the prognostic research guide-
lines.25 Another strength is the wide availability of birth and ROP 
progression data and easy access to the model that might facili-
tate screening for ophthalmologists. Identification of infants as 
potentially requiring no further screening after a defined date 
may safely decrease the number of unnecessary examinations 
for low- risk infants after affirming that the model applies to the 
particular cohort under consideration.
Our study’s limitation is its retrospective design and registry 
data, although intense efforts were made to validate incomplete 
data points. Ongoing research including photographic docu-
mentation and telemedicine will certainly decrease the vari-
ability in ROP diagnostics between ophthalmologists, and hence 
also improve sensitivity and specificity of prediction models.35 
A second limitation is the small subgroup of non- white infants 
used for validation. In many countries, screening of infants 
born <31 weeks of GA is mandatory, although in Sweden the 
current guidelines from 2020 recommend screening for GA 
<30 weeks.7 36–38 Our tool was developed to study infants born 
at GA 24 weeks (+0 days) to 30 weeks (+6 days). However, 
infants born at 31 weeks of GA or later who require screening 
based on a medical indication should be monitored closely 
and carefully, as should infants born <24 weeks of GA, all of 
whom have a high risk for developing ROP needing treatment. 
This algorithm which is aimed at identifying the time point for 
ending ROP screening is thus of limited value to these babies as 
they need screening according to guidelines. Another limitation 
is that no validation has been performed on populations from 
low- income countries where more mature infants need treatment 
for ROP due to the risk associated with unmonitored oxygen 
exposure, but also from countries with high- level neonatal care 
but with limited facilities and personnel. Continued validation, 
performed on similar and different populations is needed. The 
model parameters or even the model selection, including other 
important variables, might need to be updated to match some 
specific healthcare settings. The future implementation of this 
tool at our or any other NICU should concomitantly initiate 
a clinical study monitoring its effectiveness (including stress 
reduction), impact on patient safety as well as on the clinical 
workload and health economics.
In conclusion, the DIGIROP- Screen, an internally and 
externally validated ROP prediction tool, is available to be 
applied to infants, born at GA 24–30 weeks, at birth and 
also applied during the routine ROP screening process. The 
tool may allow ophthalmologists to reduce the number of 
stressful examinations and optimise screening efficiency by 
potentially and safely releasing many infants from unneces-
sary eye examinations. DIGIROP- Screen appears to be one 
of the more robust models predicting severe ROP requiring 
treatment.
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